RedHill Biopharma Ltd. (NASDAQ:RDHL) traded at $0.43 at close of the session on Tuesday, 11/22/22, made a downward move of -8.64% on its previous day’s price.
Looking at the stock we see that its previous close was $0.47 and the beta (5Y monthly) reads 1.96 with the day’s price range being $0.4201 – $0.466. In terms of its 52-week price range, RDHL has a high of $3.37 and a low of $0.45. The company’s stock has lost about -21.13% over that past 30 days.
RedHill Biopharma Ltd. has a market cap of $23.21 million and is expected to release its quarterly earnings report on Nov 28, 2022 – Dec 02, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.03, with the EPS growth for the year raised at -$0.13 for 2022 and $0 for next year.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $21.5 million, with a low of $21.1 million and a high of $21.9 million. The median projection represents growth adding up to -14.10% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $88.4 million, or 3.10% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the RDHL stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the RedHill Biopharma Ltd. (RDHL) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -29.31% off its SMA20 and -28.23% from its 50-day simple moving average. The RSI (14) is pointing at 29.86 while the volatility over the past week is 10.75% and jumps to 9.10% over the past one month. The beta value is 2.10, while the average true range (ATR) is currently pointing at 0.07. The average price target for the stock over the next 12 months is $1.00, with the estimates having a low of $1.00 and a high of $1.00. These price ends are -132.56% and -132.56% off the current price level respectively, although investors could be excited at the prospect of a -132.56% if the RDHL share price touches on the median price of $1.00.
Let’s briefly compare RedHill Biopharma Ltd. (RDHL) stock to its peers. We find that current price change of -8.64% and -84.43% over the past 12 months for RDHL competes that of Sanofi (SNY), which has seen its stock price rise 0.69% in the last trading session and was -9.36% over the last one year. Another of its peers Taro Pharmaceutical Industries Ltd. (TARO) has gained 3.68% previous session, and was -45.19% down over the past year, while Teva Pharmaceutical Industries Limited (TEVA) was also up 1.59% in the last session, while its price remained in the green at 2.51% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.36% and 1.18%, respectively, at close of the trading.
Coming back to RedHill Biopharma Ltd. (NASDAQ:RDHL), we note that the average 3-month trading volume was 2.91 million, while that of the preceding 10-day period stands at 2.03 million. Current shares outstanding are 52.52 million.
The insiders hold 12.96% of the company’s shares while institutions hold 8.80%. The data shows that short shares as of Oct 13, 2022, stood at 2.63 million at a short ratio of 1.45. This represents a 4.11% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 1.66 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -83.52% down in year-to-date price movement.